Johnson & Johnson (NYSE: JNJ) plunges over 2.3% in early session on Tuesday as the firm releases first-quarter 2023 earnings today. Chairman of the Board and CEO, Joaquin Duato stated that their first-quarter results demonstrate strong performance across all three segments of their business and reflect the dedication of Johnson & Johnson colleagues around the world. “With this momentum, I am looking forward to the rest of the year, which will be full of exciting catalysts that will create both short- and long-term value for patients and all of our stakeholders.”
Consumer Health’s worldwide adjusted operating sales climbed 11.3%*, with over-the-counter (OTC) goods driving the majority of the growth. TYLENOL and MOTRIN analgesics, upper respiratory treatments, IMODIUM in digestive health goods, and worldwide smoking cessation medications were major contributors to growth in OTC. NEUTROGENA and AVEENO in Skin Health/Beauty goods, as well as JOHNSON’s in Baby Care products, also contributed to growth.
Pharmaceutical global adjusted operational sales increased 7.2%, led by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, and CARVYKTI (ciltacabtagene Sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S) for the protection of the SARS-CoV-2 Virus also contributed to growth.
Sales of REMICADE (infliximab), a biologic approved for the treatment of several immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once daily therapy approved for the treatment of certain B-cell malignancies, a type of blood or lymph node cancer, and ZYTIGA (abiraterone acetate), an oral, once daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant
MedTech’s global adjusted operating sales increased 6.4%, principally due to electrophysiology products in Interventional Solutions, contact lenses in Vision, wound closure solutions in General Surgery, and orthopaedic knees. MedTech’s global operational revenues increased 11.0%, with the purchase of Abiomed accounting for 4.6% of the increase.
